Table 1.
Candidate Cytomegalovirus Vaccines in Development
| Sponsor | Vaccine Type | Study Phase | Target |
|---|---|---|---|
| Merck | Live, replication defective | Phase 2 | Congenital infection |
| Sanofi | gB, pentamer subunit | Phase 2 Preclinical | Congenital infection |
| City of Hope | pp65 subunit, adjuvant | Phase 1 | Infection in transplant recipients |
| City of Hope | MVA presenting pp65, IE1, IE2 | Phase 2 | Infection in transplant recipients |
| Moderna | gB, pentamer mRNA | Phase 2 | Congenital infection |
| GlaxoSmithKline | gB, pentamer subunit, adjuvant | Preclinical | Congenital infection |
| Hookipa | LCMV vector gB, p65 | Phase 1 | Infection in transplant recipients |
| Variations Bio | gB | Phase 1 | Congenital infection |
| Serum Institute of India | Dense bodies | Preclinical | Infection in transplant recipients |
| Queensland Institute | gB, pp65, p50 Polypeptide with TLR-9 adjuvant | Preclinical | Congenital infection |
| Pfizer | Approach not public | Preclinical | Congenital infection |
| Astellas | DNA | Failure | Infection in transplant recipients |
Abbreviations: gB, glycoprotein B; IE1 and IE2, immediate early protein 1 and 2; LCMV, lymphocytic choriomeningitis virus; mRNA, messenger RNA; MVA, modified vaccinia Ankara; TLR-9, Toll-like receptor 9.